Chemomab Therapeutics (CMMB) Total Current Liabilities (2017 - 2025)

Chemomab Therapeutics' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $1.5 million for Q4 2025.

• Quarterly Total Current Liabilities fell 54.07% year-over-year to $1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 million (down 54.07% YoY) and the FY2025 annual result came in at $1.5 million, down 54.07% from the prior year.
• Total Current Liabilities was $1.5 million for Q4 2025 at Chemomab Therapeutics, up from $1.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $7.0 million in Q1 2023 and bottomed at $1.1 million in Q3 2025.
• A 5-year average of $3.9 million and a median of $4.3 million in 2024 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 236.01% — and 2025, when it plunged 73.86%.
• Chemomab Therapeutics' Total Current Liabilities stood at $2.6 million in 2021, then surged by 154.68% to $6.7 million in 2022, then slipped by 28.32% to $4.8 million in 2023, then sank by 33.48% to $3.2 million in 2024, then plunged by 54.07% to $1.5 million in 2025.
• Business Quant data shows CMMB's Total Current Liabilities at $1.5 million in Q4 2025, $1.1 million in Q3 2025, and $1.4 million in Q2 2025.